Roughly 70% breast cancers fall into the ER+ category, 20% fall into the HER2+ category, and the remaining 10%, which do not exhibit ER/PR expression or HER2 amplification/overexpression, are referred to as triple negative. The gene discussed is PGR; the disease is breast carcinoma.